Host
Qinggong Wu: Chief Investment Officer, Tongxieyi; Former Vice Chairman, China Pharmaceutical Enterprise Management Association

09:00-09:05　Opening Remarks

09:05-09:25　Path Planning & Key Regulatory Challenges for Biotech IPOs in Hong Kong
William Ji: Founding Partner, Tian Yuan Law Firm

09:25-09:45　Hong Kong Listing of Biopharmaceutical Enterprises: Regulatory Logic & Review Focus
David Cheng: Managing Director & Head of Asia Corporate Finance, BofA Securities

09:45-10:05　A New Chapter of Hong Kong Capital Market
Jacqueline Jiang: Vice President, Global Listing Services, Hong Kong Exchanges and Clearing Limited (HKEX)

10:05-10:25　Reshaping & Breakthrough: Dynamics and Practice of Hong Kong IPO Issuance in the New Cycle
Chenming Xu: Member of Investment Banking Management Committee, CITIC Securities; Head of International Business, Global Healthcare Sector

10:25-10:50　Break

10:50-11:50　Roundtable: New Landscape & Path Planning for Innovative Pharma Enterprises Listing in Hong Kong
Darren Ji (Host): CEO, Elpiscience Biopharma
Tony Yin: Managing Director, Global Investment Banking, BofA Securities
Li Zhong: Executive Director, Healthcare Group, China International Capital Corporation (CICC); Sponsoring Representative
William Ji: Founding Partner, Tian Yuan Law Firm
Lin Ye: CFO & Chief Strategy Officer, Beizhen Pharma; Former Managing Director, Goldman Sachs
Eva Chu: Listing Director, Tian Yuan Law Firm

13:30-13:35    Opening Remarks
Zhenghong Gao：CEO, Cofounder, Uni-Pioneers

13:35-14:00    Pioneering mRNA cell therapies for the treatment of autoimmune diseases
Carsten Brunn：CEO, Chairman, Cartesian Therapeutics

14:00-15:00    Panel: Harnessing China's Innovation to Accelerate Global Drug Developmen
Zhenghong Gao ((Moderator)：CEO, Cofounder, Uni-Pioneers        
Vivian  Li (Co-moderator)：Investor, K2VC         
Carsten Brunn：President, CEO, Chairman, Cartesian Therapeutics        
Alex Zhavoronkov：Founder, CEO, Insilico Medicine        
Linda Zhang：Partner, Innokylin Capital        
Koji Yasuda：Principle, Fast Track Initiative, Inc.        
Jing Niu：Sr. Investment Director, Huatai-GenScript Capital        
Pengcheng Zhu：CEO, ATLATL Innovation Center        

敬请期待

Session Planners
Genhong Cheng: Distinguished Professor at Guangzhou Laboratory, Strategic Advisor of Guangzhou Pharmaceutical Holdings Limited (GPHL), Fellow of the American Academy of Microbiology, Tenured Professor at UCLA
Wei Peng: Deputy General Manager, Guangzhou Pharmaceutical Holdings Limited (GPHL)
Hong Liu: Head of the Scientific Research Project Management Department (Postdoctoral Workstation) of Guangzhou Pharmaceutical Holdings Limited (GPHL), Board Director of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, Chairman and General Manager of Guangzhou Baiyunshan XIHE Health Pharmaceutical Co., Ltd.

Opening Remarks
Genhong Cheng: Distinguished Professor at Guangzhou Laboratory, Strategic Advisor of GPHL, Fellow of the American Academy of Microbiology, Tenured Professor at UCLA

Leader's Remarks
Wei Peng: Deputy General Manager, GPHL

Keynote Presentation by GPHL Group: Empowering Innovation as a Traditional Pharma – GPHL Embarks on a New Journey
Jian Liu: Strategic Scientist, GPHL

Drug Discovery Targeting GPCRs and the Pharmacology of Sensation and Perception
Jinpeng Sun: Professor at Peking University and Shandong University, Investigator of the New Cornerstone Science Foundation, Dean of the Advanced Medical Research Institute of Shandong University, Chair of the Department of Biophysics, Peking University Health Science Center, Chief Scientist of Jinan Star Conjugate Biopharmaceutical Co., Ltd.

Research and Development of Self-developed LNP-assisted mRNA Innovative Drugs: Clinical Translation from Tumor Therapeutic Vaccines to In Vivo CAR-T Cell Therapy
Xiangrong Song: Professor and Doctoral Supervisor, Director of the mRNA Research Platform at the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

PharmAgents: A Novel Paradigm of AI-Powered Innovative Drug Discovery
Bowen Gao: CEO, Aifei Intelligent Pharma

Roundtable Discussion: Innovation and Transformation Paths for Traditional Pharmaceutical Companies (Topic TBD)
Jian Liu (Moderator): Strategic Scientist, GPHL
Yongkui Sun: Member of the National Academy of Engineering of the United States, Director of Shanghai Innovative Drug Research and Development Center
Xiaobin Wu: President & COO, BeiGene
Yuhong Geng: Executive President, Yifan Pharmaceutical Co., Ltd.

13:30-13:40　Opening Speech
Guoguang Zhu:  Co-Director of Research Institute, Head of Grand Consumption Group, & Chief Analyst of Pharmaceutical Industry, Soochow Securities

13:40-14:10　Dialogue: Overseas Expansion and Commercialization of Innovative Drugs: Challenges and Breakthroughs
William Wu: Chairman of the Board of Everest Medicines, Executive Operating Partner of CBC Group
Guoguang Zhu (Host):  Co-Director of Research Institute, Head of Grand Consumption Group, & Chief Analyst of Pharmaceutical Industry, Soochow Securities

14:10-14:30　China Assets from the Perspectives of US Buyers: Best Practices and How to Optimize Deal Value
Eric Liu: Managing Director, Locust Walk

14:30-14:50　AI-Driven Drug Discovery: The Global Landscape and Insilico Medicine's Approach
Alex Zhavoronkov: Founder & CEO, Insilico Medicine

14:50-15:30　Roundtable Discussion: Future Forward: Competing and Collaborating—The Next Chapter of Global Life Sciences Partnerships
Jiawei Tang: Co-Founder & COO, GB-Partner
Alex Zhavoronkov: Founder & CEO, Insilico Medicine
Ester Caffarel-Salvador: Director of Strategic Innovation, Chiesi
Yingyao Chen: Associate Dean of Public Health, Fudan University
Simon Wang: Founder and CSO of SynAgentics Biosciences
Irtaza Haider: Managing Partner, K2 BioCapital

15:30-15:50　Break

15:50-16:10　Diversified Payment for Innovative Drugs: Inter-Departmental Policy Coordination
Roben Liang: Standing Committee Member and Research Fellow, Special Committee of Public Hospital Medical Insurance Management, China Medical Insurance Research Association

16:10-16:30　Establishing a Diversified Payment Mechanism for Innovative Drugs: Reflections and Recommendations
Leo Zhao: General Manager, Intelligent Medicine Business Unit, MediTrust Health

16:30-16:50　Japan's Medical Insurance System: Current Status Analysis and Implications for China
Jianghu Piao: Manager of Overseas Business Development Office, Corporate Strategy Headquarters, Toho Holdings Co., Ltd.; Chairman, Hubei Gongchuang Pharmaceutical Co., Ltd.

16:50-17:30　Roundtable: Innovative Group Health Insurance for Innovative Drugs Payment: Policy Opportunities and Ecosystem Building
Hongde Xiao (Host):  Chief Analyst of Innovative Drugs, Soochow Securities
Houjia Liu: Director, Shanghai Center for Biomedical Development
Steven Wang:  Business Head, CPIC Health Research Institute
Yun Xia: Director of Medical Insurance Office & Associate Research Fellow, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
Gang Gong: Chairman, Beijing Huibaofuda Health Technology Co., Ltd.

Planner
Xiao Liu: Vice President, CoJourney; Chief Brand Officer, TONACEA

09:30-09:35　Opening Remarks
Xiao Liu: Vice President, CoJourney; Chief Brand Officer, TONACEA

09:35-09:50　Round-robin Interview
Yuan Cai (Host): Head of AAV, Metabolic Health Lab, Shanda Group
Xiao Xiao: Chairman & CSO, Belief BioMed
Zhenhua Wu: Founder, Chairman & CEO, Exegenesis Bio
Jingmin Zhou: Co-Founder & CEO, Genemagic Biosciences
Fenghua Wang: Founder, Chairman & CEO, Innostellar Biotherapeutics
Gong Chen: Founder & Chairman, NeuExcell Therapeutics
Biao Dong: Founder, Real&Best Biotech

09:50-10:30　Debate: Should Gene Therapy Expand to Broader Indications?
Alex Chia Yu Chang (Pro): Founder & CEO, Juvensis Therapeutics
Yuanyuan Xu (Pro): Chairman, Cure Genetics
Shengjiang Liu (Pro): Chairman & CEO, Avirmax
Chunyan He (Con): Founder & CEO, GenAssist
Kun Wu (Con): Founder, Qisejin Rare Disease
Wei Wang (Con): CEO, Chigenovo

10:30-11:10　Panel Discussion I: The Unshared Joy of Reaching the Industry Summit
Hongyuan Wang (Host): CEO, Gritgen Therapeutics
Lu Gao: CEO, Euhearing Therapeutics
Piming Zhao: Founder, TaogenBio
Lijun Wang: Founder & CEO, CoJourney
Luke Li: CEO of Neurophth Therapeutics
Xiao Xiao: Chairman & CSO, Belief BioMed
Fenghua Wang: Founder, Chairman & CEO, Innostellar Biotherapeutics

11:10-11:45　Panel Discussion II: Gene Therapy — Boao, 818 or 828
Zhenhua Wu (Host): Founder, Chairman & CEO, Exegenesis Bio
Guang Qu: Co-Founder, NGGT
Biao Dong: Founder, Real&Best Biotech
Yue Chen: Vice President of Business Development, WX ATU
Hongyuan Wang: CEO, Gritgen Therapeutics

11:45-12:30　Panel Discussion III: Surprises in the Future of Gene Therapy
Yuan Cai (Host): Head of AAV, Metabolic Health Lab, Shanda Group
Jingmin Zhou: Co-Founder & CEO, Genemagic Biosciences
Alex Chia Yu Chang: Founder & CEO, Juvensis Therapeutics
Yuanyuan Xu: Chairman, Cure Genetics
Nina Zhang: Executive Deputy Director, Clinical Research & Gastroenterology, Nanjing Drum Tower Hospital; Founder, Motigen BioMed Inc.